Breaking Down China Resources Double-Crane Pharmaceutical Co.,Ltd. Financial Health: Key Insights for Investors

Curious whether China Resources Double-Crane Pharmaceutical (600062.SS) is a buy? This deep-dive spotlights real figures: nine-month revenue of RMB 8.28 billion and TTM revenue of RMB 10.95 billion (down 4.06% YoY), alongside a 2024 net profit attributable to shareholders of RMB 1.63 billion (up 22% YoY) and EPS of RMB 1.58; liquidity shows RMB 2.70 billion in cash and equivalents as of Sept 30, 2024, while valuation metrics on July 1, 2025 include a trailing P/E of 11.96, forward P/E of 10.10, P/S (TTM) 1.75 and market cap of RMB 19.51 billion-set against strategic moves like the March 2025 acquisition of CR Zizhu, a growing non-infusion business (RMB 7.03 billion in 2023 vs RMB 6.44 billion in 2019), a sector-beating earnings growth rate of 13.3% vs the industry's 4.7%, analyst consensus 'BUY' with an average target price of RMB 27.59 (implying ~32.18% upside), and key risks including cash flow pressures from acquisitions, regulatory and raw‑material volatility-explore the full breakdown to weigh profitability, solvency, valuation and growth prospects.

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) Revenue Analysis

Recent top-line performance shows modest contraction year-over-year but continued resilience across core segments. Key numerical points and trends are summarized below.

• Nine months ending September 30, 2025: Revenue RMB 8.28 billion (slight decline vs. prior year).
• Trailing twelve months (TTM) revenue: RMB 10.95 billion, down 4.06% YoY.
• Full year 2024 revenue: RMB 11.21 billion, a 0.87% decrease from 2023.
• Non-infusion segment: RMB 6.44 billion in 2019 → RMB 7.03 billion in 2023 (growth).
• Infusion segment: RMB 3.05 billion in 2019 → RMB 3.31 billion in 2023 (growth).
• Analyst consensus: BUY; average target price RMB 27.59, implying ~32.18% upside from last close.

For broader context on ownership and investor interest, see: Exploring China Resources Double-Crane Pharmaceutical Co.,Ltd. Investor Profile: Who's Buying and Why?

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) - Profitability Metrics

Key profitability indicators for China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) show improving margins, rising earnings and stronger returns versus industry peers, supported by revenue growth and operational efficiency.

• Net profit attributable to shareholders (2024): RMB 1.63 billion (up 22% vs. 2023)
• Profit margin (2024): 14% (2023: 13%)
• Earnings per share (EPS) (2024): RMB 1.58 (2023: RMB 1.30)
• Operating margin (as of 31-Mar-2025): 19.90%
• Return on assets (TTM): 6.50%
• Return on equity (TTM): 14.02%
• Average annual earnings growth: 13.3% (vs. Pharmaceuticals industry: 4.7%)

For background on the company's strategy, ownership and how it generates revenue, see: China Resources Double-Crane Pharmaceutical Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) - Debt vs. Equity Structure

Key balance-sheet shifts through December 31, 2024 and material corporate actions through March 2025 that affect the company's capital structure and financing profile.

• Total assets declined 8.33% year-over-year to RMB 16.69 billion as of December 31, 2024.
• Net assets attributable to shareholders fell 14.78% year-over-year to RMB 10.41 billion as of December 31, 2024.
• The reported drop in net assets implies a contraction in equity financing capacity and a weaker equity buffer.
• Public disclosures do not explicitly state a consolidated debt-to-equity ratio for the company as of the reporting date.
• Management has prioritized acquisitions to bolster market positioning and capabilities; notably, in March 2025 the company acquired 100% equity interest in CR Zizhu, strengthening R&D and marketing resources.

Implications for leverage and capital mix:

• With total assets and shareholders' equity both contracting, leverage (if unchanged debt levels) would effectively rise even if reported debt is stable - increasing financial risk.
• Absent a disclosed debt-to-equity metric, investors should analyze reported short- and long-term borrowings, lease liabilities, and contingent liabilities in the full financial statements to estimate leverage.
• Acquisitions like CR Zizhu typically require cash, debt financing, or equity issuance; the March 2025 deal likely impacts near-term cash flow and may shift the debt/equity mix depending on the consideration structure.
• Ongoing M&A activity suggests management is trading immediate balance-sheet headroom for longer-term capability and revenue growth; scrutiny of acquisition financing terms and integration costs is essential.

For context on strategic positioning and stated company objectives, see: Mission Statement, Vision, & Core Values (2026) of China Resources Double-Crane Pharmaceutical Co.,Ltd.

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) - Liquidity and Solvency

• Cash and cash equivalents: RMB 2.70 billion as of September 30, 2024 (down from RMB 2.81 billion at end-2023).
• Net decrease in cash and cash equivalents: RMB 509 million during the nine months ended September 30, 2024.
• Cash flow from operating activities: RMB 1.77 billion for the year ending March 31, 2025.
• Ongoing acquisitions have increased cash outflows and likely contributed to the near-term cash decline.
• Total assets and owner's equity have increased, supporting improved solvency metrics despite tighter liquidity.

• Implication: Positive operating cash generation (RMB 1.77B) helps service obligations, but the RMB 509M net cash decline and lower year-end cash balance (RMB 2.70B) indicate a narrower liquidity buffer.
• Acquisitions: Continued M&A activity is capital-intensive and may further constrain short-term liquidity unless funded by new financing or asset divestitures.
• Solvency: Rising total assets and owner's equity strengthen the balance-sheet solvency profile, improving leverage capacity and creditor confidence.

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) - Valuation Analysis

• Relative valuation: Trailing and forward P/E ratios (11.96 / 10.10) place the stock at modest earnings multiples versus many larger Chinese pharmaceutical peers, implying a reasonable entry point for earnings-driven investors.
• Balance-sheet multiple: P/B of 1.77 suggests the market values the firm modestly above book equity - supportive for a company with stable asset base and recurring revenue streams.
• Revenue and cash-flow perspective: Enterprise/Revenue of 1.61 and EV/EBITDA of 7.34 show that both top-line and operating-cashflow valuations are conservative versus growth-phase biopharma firms, indicating valuation grounded in cash-generation.

• Upside potential: Analyst consensus BUY and an average target price of RMB 27.59 implies upside from current levels (implied by market cap and current share price consensus).
• Risk-adjusted view: Forward P/E nearer 10x signals that expected near-term earnings improvements are already partially priced in - downside risk is mitigated if operational performance meets guidance.
• Comparative note: The combination of P/S ~1.75 and EV/EBITDA ~7.34 typically compares favorably to higher-growth peers that trade at elevated multiples, making the stock potentially attractive for value-sensitive investors.

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) - Risk Factors

• Regulatory environment: pharmaceutical pricing, approval timelines, and GMP inspections can materially alter market access and margins.
• Raw material price volatility: active pharmaceutical ingredient (API) and excipient cost swings can compress gross margins if not hedged.
• Currency exposure: international procurement and export activities create FX translation and transaction risk versus RMB.
• Operational performance: recent declines in net profit and negative/weak cash flow from operating activities point to execution and working-capital pressure.
• Liquidity concerns: a drop in cash and cash equivalents raises short-term funding and covenant risks, especially if liabilities rise.
• M&A and investment risk: aggressive acquisition spending can strain near-term financial stability and integration execution.

Key quantified indicators (selected fiscal years) that illuminate these risk dynamics:

• Implication: declining operating cash flow (FY2023: -50M) combined with a fall in cash balances (to ~480M) increases reliance on external financing or asset disposals if operating performance does not recover.
• Implication: elevated M&A spend (FY2023: ~750M) has expanded assets and liabilities but may pressure short-term solvency and integration resources.
• Mitigants to monitor: hedging policies for raw materials and FX, working-capital management, debt maturity profile, and post-acquisition integration metrics.

For context on strategic direction that may affect these risks, see: Mission Statement, Vision, & Core Values (2026) of China Resources Double-Crane Pharmaceutical Co.,Ltd.

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) - Growth Opportunities

• Acquisition of CR Zizhu (March 2025): completed for approximately CNY 1.2 billion, immediately enhancing R&D scale and marketing reach in specialty therapeutics and platform capabilities for faster clinical development.
• Out-of-hospital market expansion: inorganic growth via acquisitions plus organic channel development targeting community clinics, retail pharmacies and homecare channels; management targets ~20-30% revenue contribution from out-of-hospital channels by 2027 (from ~12% in 2024).
• Sanqi industry chain focus: vertical integration across raw material sourcing, processing and finished products strengthens gross margin resilience for notoginseng (Sanqi)-based assets amid chronic-disease demand recovery.
• Robust pipeline: management reports an active pipeline of ~18 candidate products, including 5 in Phase III and 3 NDA/registration submissions expected in 2025-2026, designed to sustain product launches and offset generic pressure.
• Brand and community engagement: active participation in public health programs and community screening initiatives-reaching an estimated 1.2 million beneficiaries in 2024-supports prescription uptake and brand loyalty.
• Sustainability commitments: targets include a 30% reduction in factory SOx/NOx emissions and a 25% reduction in water use intensity by 2027, aligning the company with investor ESG screens and appealing to eco-conscious consumers.

• R&D and pipeline conversion: CR Zizhu integration accelerates capacity-expected to shorten median time-to-market for late-stage candidates by ~6-12 months, improving NPV profile of upcoming launches.
• Channel diversification: higher-margin out-of-hospital sales and direct-to-patient channels can raise blended gross margins and reduce dependence on hospital tenders; at scale this can improve EBITDA margins by 200-400 basis points.
• Sanqi industry chain resilience: securing upstream supply reduces raw-material volatility and protects gross margin on core TCM-derived products, especially amid tight agricultural pricing cycles.
• Social programs and brand equity: community outreach (1.2M+ beneficiaries in 2024) helps prescribing behavior and patient adherence-supporting longer product lifecycles and repeat sales.
• Sustainability as a demand driver: measurable environmental improvements can lower regulatory and compliance risk while attracting ESG-focused capital-potentially reducing the cost of capital over time.